Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

Abstract Background To describe the patterns of second-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel treatment in a Spanish population, to identify the factors associated with those patterns, and to compare the efficacy and safety of the trea...

Full description

Bibliographic Details
Main Authors: Javier Puente, Aranzazu González-del-Alba, Núria Sala-Gonzalez, María José Méndez-Vidal, Alvaro Pinto, Ángel Rodríguez, José Miguel Cuevas Sanz, Jacobo Rodrigo Muñoz del Toro, Eduardo Useros Rodríguez, Ángela García García-Porrero, Sergio Vázquez
Format: Article
Language:English
Published: BMC 2019-08-01
Series:BMC Cancer
Subjects:
Metastatic castration-resistant prostate cancer
Abiraterone acetate
Cabazitaxel
Chemotherapy
Sequence
Online Access:http://link.springer.com/article/10.1186/s12885-019-5974-9

Internet

http://link.springer.com/article/10.1186/s12885-019-5974-9

Similar Items